Palm et al. (2003) studied the in vivo disposition kinetics of trastuzumab mAb (anti‐HER2/neu) in mice bearing ovarian carcinoma using positron emission tomography (PET) imaging coregistered with standard MRI. This evidence concerns the gene ERBB2 and ovarian carcinoma.